Sign in

You're signed outSign in or to get full access.

Colleen Coozy

Vice President and Senior Research Analyst at Baird

Colleen Kusy is a Vice President and Senior Research Analyst at Baird, specializing in biotechnology equity research and covering a range of companies developing innovative therapies across therapeutic areas. She covers firms such as Ocular Therapeutix and engages with leading biopharmaceutical companies on pipeline progress and clinical trial developments, contributing actionable insights to investors. Renowned for her analytical rigor, Kusy was named a 'Rising Star of Equity Research' by Business Insider in 2023, reflecting her growing recognition and effective stock coverage. She launched her career in Fixed Income Capital Markets before moving to biotechnology research at Baird in 2014, and holds a BBA in Finance and a BA in French and Francophone Studies from Villanova University.

Colleen Coozy's questions to OCULAR THERAPEUTIX (OCUL) leadership

Question · Q3 2025

Colleen Coozy asked about the specific details expected in the SOL1 top-line data, including six-month BCVA, and which data points would be most crucial for building confidence in the read-through to SOLar.

Answer

Pravin U. Dugel, Executive Chairman, President and CEO, reiterated that SOL1's primary goal is a superiority label, while SOLar focuses on clinical relevance. He affirmed the company's commitment to providing SOL1 data that instills confidence in SOLar's success, highlighting SOLar's de-risked patient randomization and singular 56-week endpoint as existing reasons for confidence.

Ask follow-up questions

Fintool

Fintool can predict OCULAR THERAPEUTIX logo OCUL's earnings beat/miss a week before the call